Welcome to Fierce Biotech's fifth annual layoff tracker, a resource designed to keep pace with the sector's steady stream of ...
With partner Eli Lilly’s help, the radiopharmaceutical drugmaker priced one of the sector’s largest new stock offerings in ...
24/7 Wall St. on MSN
Biotech could be one of 2026’s biggest winners, and this ETF is perfectly positioned
Quick Read FBT returned 29% over the past year and gained 5.4% in the first week of 2026. Federal Reserve officials forecast ...
After a prolonged funding chill, investors say 2026 is shaping up for continued dealmaking and diversified bets beyond ...
It sounds like Lilly did just that. The U.S. pharma announced Wednesday that it was paying $14 per share of Ventyx—more than ...
Stocktwits on MSN
Ventyx’s $1.2B buyout by Eli Lilly proves timing often beats conviction in biotech investing — a VC explains
Booth said timing drove sharply different investor outcomes in Ventyx. ・Clear Street said Lilly was a logical buyer and cut ...
A bevy of other companies also brought in money on Thursday, including Alveus Therapeutics, Diagonal Therapeutics, ...
XBI biotech ETF surged 65% as M&A heats up, but 2026 brings headwinds and tougher gains. Click here for a detailed analysis.
Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing ...
O4, Jared Holz of Mizuho joined ‘Power Lunch’ on CNBC to talk about how to play biotech moving into 2026. Holz noted that ...
A life-sciences job in Boston used to be a sure path to a high-paying career, but empty labs and unemployed grads now herald ...
Explore the Latest Research Peptides from Biotech Labz Supply Sebastopol, United States – January 4, 2026 / Biotech Labz Supply / Biotech Labz Supply has revealed an exciting enhancement of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback